% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@PHDTHESIS{Zhang:969118,
author = {Zhang, Xing},
othercontributors = {Eschweiler, Jörg and Bleilevens, Christian},
title = {{O}steoblast derived extracellular vesicles induced by
dexamethasone: a novel biomimetic tool for enhancing
osteogenesis in vitro},
school = {Rheinisch-Westfälische Technische Hochschule Aachen},
type = {Dissertation},
address = {Aachen},
publisher = {RWTH Aachen University},
reportid = {RWTH-2023-08953},
pages = {1 Online-Ressource : Illustrationen, Diagramme},
year = {2023},
note = {Veröffentlicht auf dem Publikationsserver der RWTH Aachen
University; Dissertation, Rheinisch-Westfälische Technische
Hochschule Aachen, 2023},
abstract = {Extracellular vesicles (EVs) are newly appreciated
communicators involved in intercellular crosstalk, and have
emerged as a promising biomimetic tool for bone tissue
regeneration, overcoming many of the limitations associated
with cell-based therapies. However, the significance of
osteoblast-derived extracellular vesicles on osteogenesis
has not been fully established. In this present study, we
aim to investigate the therapeutic potential of
extracellular vesicles secreted from consecutive 14 days of
dexamethasone-stimulated osteoblasts (OB-EVDex) to act as a
biomimetic tool for regulating osteogenesis, and to
elucidate the underlying mechanisms. OB-EVDex treated groups
are compared to the clinically used osteo-inductor of BMP-2
as control. Our findings revealed that OB-EVDex have a
typical bilayer membrane nanostructure with an average
diameter of 178 ± 21 nm, and that fluorescently labeled
OB-EVDex were engulfed by osteoblasts in a time-dependent
manner. The proliferation, attachment, and viability
capacities of OB-EVDex-treated osteoblasts were
significantly improved when compared to untreated cells,
with the highest proliferative rate observed in the OB-EVDex
+ BMP-2 group. Notably, combinations of OB-EVDex and BMP-2
markedly promoted osteogenic differentiation by positively
upregulating osteogenesis-related gene expression levels of
RUNX2, BGLAP, SPP1, SPARC, Col 1A1, and ALPL relative to
BMP-2 or OB-EVDex treatment alone. Mineralization assays
also showed greater pro-osteogenic potency after combined
applications of OB-EVDex and BMP-2, as evidenced by a
notable increase in mineralized nodules (calcium deposition)
revealed by Alkaline Phosphatase (ALP), Alizarin Red (ARS),
and von Kossa staining. Therefore, our findings shed light
on the potential of OB-EVDex as a new therapeutic option for
enhancing osteogenesis.},
cin = {533500-3 ; 931510},
ddc = {610},
cid = {$I:(DE-82)533500-3_20140620$},
pnm = {DFG project 429837092 - Differenzierte Chirurgische und
Immunologische Kontrolle nach Polytrauma im Langzeit
Großtiermodell (429837092)},
pid = {G:(GEPRIS)429837092},
typ = {PUB:(DE-HGF)11},
doi = {10.18154/RWTH-2023-08953},
url = {https://publications.rwth-aachen.de/record/969118},
}